OakChart

ElectroCore Inc

ECORHealthcare·Medical Devices·USA·Micro·NASD·Nov 11 • 12:04 PM ET

8.26+0.54 (7.01%)
2026-11-11 18:04 CET
Market cap
71.22 USD m
Revenue, TTM
37.97 USD m
Net income, TTM
-12.70 USD m
Free cash flow, TTM
-10.90 USD m
EPS diluted, TTM
-1.43
P/E
-
Compare

Price

ECOR against its 20, 50 and 200-day averages
2050200beat
6.008.0010.0012.00309K619KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ECORclose 8.2620-day 7.7250-day 9.18200-day 7.758.2652w high

35.0% under the 52-week high of 12.70 on 22 Sep 2026. 52-week low 4.41 on 18 Dec 2025. Last 15 sessions, 29.9% high to low

Profile

ECOR
52-week range, 46% of the way up
4.4112.70

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. It develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The company was founded by Joseph P. Errico, Steven M. Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Rockaway, NJ.

Employees83
IPOJun 22, 2018
Beta1.19
ATR, 14d0.83
Rel volume0.58
Short float5.80%
Insider own32.89%
Inst own13.30%

Snapshot

6 groups

Valuation

Index-
Market Cap76.21M
Enterprise Value78.40M
Income-12.70M
Sales37.97M
Book/sh-0.27
Cash/sh0.81
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees83
IPOJun 22, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S2.01
P/B-
P/C10.16
P/FCF-
EV/EBITDA-
EV/Sales2.06
Quick Ratio0.97
Current Ratio1.34
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.43
EPS next Y-0.23
EPS next Q-0.17
EPS this Y27.03%
EPS next Y80.90%
EPS next 5Y-
EPS past 3/5Y29.44% 28.87%
Sales past 3/5Y55.06% 55.74%
EPS Y/Y TTM20.47%
Sales Y/Y TTM27.26%
EPS Q/Q66.64%
Sales Q/Q11.52%
EarningsNov 04 AMC
EPS/Sales Surpr.52.21% -11.30%

Ownership

Insider Own32.89%
Insider Trans-2.87%
Inst Own13.30%
Inst Trans10.44%
ROA-65.70%
ROE-478.70%
ROIC-196.11%
Gross Margin86.13%
Oper. Margin-33.15%
Profit Margin-33.46%
SMA207.02%
SMA50-9.99%
SMA2006.55%
Trades-

Technical

Shs Outstand9.17M
Shs Float6.19M
Short Float5.80%
Short Ratio3.82
Short Interest0.36M
52W High12.70 -34.95%
52W Low4.41 87.32%
Volatility16.54% 11.29%
ATR (14)0.83
RSI (14)50.34
Beta1.19
Rel Volume0.58
Avg Volume93.93K
Volume23,143

Performance

Perf Week-1.66%
Perf Month-1.54%
Perf Quarter-16.89%
Perf Half Y30.71%
Perf YTD84.19%
Perf Year31.13%
Perf 3Y43.92%
Perf 5Y-40.97%
Perf 10Y-
Recom1.00
Target Price19.04
Prev Close7.72
Price8.26
Change %7.01%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
Aug 14, 2020UpgradeBBTIG ResearchNeutral → Buy$3.50-57.6%
Nov 14, 2019DowngradeJJMP SecuritiesMkt Outperform → Mkt Perform
Sep 26, 2019ResumedCCantor FitzgeraldNeutral$9+8.9%
May 30, 2019DowngradeCCantor FitzgeraldOverweight → Neutral
May 15, 2019DowngradeBBTIG ResearchBuy → Neutral
May 09, 2019InitiatedNNoble Capital MarketsOutperform
Sep 21, 2018InitiatedCCantor FitzgeraldOverweight

Peers

Mkt cap
TickerCompanyMkt cap
STIMNeuronetics Inc129.41M
BWAYBrainsway Ltd ADR439.53M
MOBIMobia Medical Inc423.10M
NXLNexalin Technology Inc1.79M
CVRXCVRx Inc20.17M
NPCENeuroPace Inc442.66M
LIVNLivaNova PLC4.98B
NYXHNyxoah SA90.30M
INSPInspire Medical Systems Inc1.79B
NMTCNeuroOne Medical Technologies Corp7.29M

Insider trading

latest 14 of 21
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Errico Thomas J.DirectorSep 14 '26Buy9.825,00049,082363,904Sep 22 07:00 AM
Lev Joshua S.CFO and Interim PresidentAug 21 '26Option Exercise4.5012,00054,00096,889Aug 25 05:30 PM
Lev Joshua S.CFO and Interim PresidentAug 24 '26Option Exercise4.505,00022,50089,889Aug 25 05:30 PM
Lev Joshua S.CFO and Interim PresidentAug 25 '26Option Exercise4.503,00013,50087,889Aug 25 05:30 PM
Lev Joshua S.CFO and Interim PresidentAug 21 '26Sale10.2212,000122,64084,889Aug 25 05:30 PM
Lev Joshua S.CFO and Interim PresidentAug 24 '26Sale9.885,00049,40084,889Aug 25 05:30 PM
Lev Joshua S.CFO and Interim PresidentAug 25 '26Sale9.363,00028,08084,889Aug 25 05:30 PM
Errico Thomas J.DirectorAug 13 '26Buy9.855,00049,272343,332Aug 17 06:19 AM
Goldberger Daniel SFormer Officer & DirectorApr 23 '26Sale6.8080,000544,000211,471Jun 12 06:12 PM
Lev Joshua S.CFO and Interim PresidentMay 28 '26Sale9.006,66760,00384,889May 29 04:05 PM
Joshua S. LevInterim President and Chief FiMay 27 '26Proposed Sale8.916,66759,403May 27 08:40 PM
PATTON THOMAS MDirectorMay 22 '26Proposed Sale7.2485,000615,658May 27 01:17 PM
Errico Thomas J.DirectorMay 21 '26Buy5.999,99259,852360,071May 26 08:52 AM
Lev Joshua S.CFO and Interim PresidentMay 22 '26Sale6.503,00019,50091,556May 22 06:11 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 206
  • electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (GlobeNewswire)
  • ElectroCore Halves Its Loss And Beats On EPS, But A Revenue Miss, Slowing Growth And A Guidance Cut Push The Story Into 2027 (Earnings Whispers) +16.18%
  • electroCore Announces Third Quarter 2026 Financial Results (GlobeNewswire)
  • ElectroCore Needs An 18% Sequential Jump To Prove Its Sales Overhaul Is Working (Earnings Whispers)
  • electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026 (GlobeNewswire)
  • Loading…
  • electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN) (GlobeNewswire) +8.51%
  • fMRI Study Suggests Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) Accelerates Neural Processes in Visual Skill Learning (GlobeNewswire)
  • electroCore to Present at Planet MicroCap Toronto 2026 powered by MicroCapClub (GlobeNewswire)
  • electroCore to Participate at H.C. Wainwright Global Investment Conference (GlobeNewswire)
  • electroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers (GlobeNewswire)
  • electroCore's Truvaga Named Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards (GlobeNewswire)
  • electroCore Announces Second Quarter 2026 Financial Results (GlobeNewswire) +20.75%
  • electroCore to Participate in Upcoming Investor Conferences (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.130-0.272-0.1359.6910.925
2026Q22026-08-06-0.330-0.422-0.3259.459.495
2026Q12026-05-06-0.590-0.612-0.5899.589.015
2025Q42026-03-19-0.340-0.402-0.3799.249.105
2025Q32025-11-05-0.400-0.400-0.4038.697.895
2025Q22025-08-06-0.440-0.325-0.4417.387.254
2025Q12025-05-07-0.470-0.483-0.4656.726.854
2024Q42025-03-12-0.370-0.300-0.4857.057.055
2024Q32024-11-13-0.310-0.326-0.3096.556.715
2024Q22024-08-07-0.380-0.430-0.3776.145.605
2024Q12024-05-08-0.530-0.588-0.5305.444.795
2023Q42024-03-13-0.610-0.592-0.6095.195.035
2023Q32023-11-08-0.680-0.697-0.6784.513.776
2023Q22023-08-09-1.030-0.963-1.0323.553.556
2023Q12023-05-03-1.240-0.996-1.2372.782.845
2022Q42023-03-08-1.220-1.116-1.2212.562.365

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-23.100-22.775-23.0502.392.66
2020FY-9.000-8.826-9.0433.503.47
2021FY-4.350-4.375-4.3645.455.48
2022FY-4.690-4.602-4.6878.598.38
2023FY-3.420-3.334-3.41516.0315.87
2024FY-1.590-1.502-1.58825.1825.19
2025FY-1.650-1.724-1.65032.0331.92
2026FY--1.204--40.42
2027FY--0.230--53.38
2028FY-0.353--66.61
2029FY-0.410--73.78
2030FY-0.800--84.85

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0550311.5010.9111.90
2026Q4S2026-11-0450011.9611.7412.37
2026Q4S2026-10-2451011.9611.7412.37
2026Q4S2026-10-2151111.9611.7412.37
2026Q4S2026-08-2153211.9611.7412.37
2026Q4S2026-08-1052211.8611.4012.37
2026Q4S2026-08-0752111.9311.4012.37
2026Q4S2026-07-2950011.8310.9713.02
2026Q4S2026-07-2150111.8310.9713.02
2026Q4S2026-06-0350311.8310.9713.02
2026Q4S2026-05-2951311.8310.9713.02
2026Q4S2026-05-1551411.8310.9713.02
2026Q4S2026-05-0752312.1510.9713.02
2026Q4S2026-03-2052212.3211.2413.00

Estimate history

EPS, annual-19.031-17.789-23.05-9.043-4.364-4.687-3.415-1.588-1.646-1.4277
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.309-0.485-0.465-0.441-0.403-0.379-0.589-0.325-0.135
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0.8110.9932.393.4965.4518.59216.0325.18232.03237.97
Period201720182019202020212022202320242025TTM
Sales, quarterly6.5547.0466.7197.3818.6899.2439.5849.459.69
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual1.8811.9631.9893.0374.7144.7456.0036.6518.0049.174
Period201720182019202020212022202320242025MRQ
Shares, quarterly6.5076.6517.427.4667.6358.0048.1269.0029.174
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue37.9732.0325.1816.038.595.453.502.390.99
Cost of Goods Sold Incl. D&A5.274.243.792.801.621.391.741.160.58
Gross Profit32.7027.7921.4013.236.984.071.761.230.41
Selling, General and Administrative Excl. Other45.2840.9433.5632.0329.8524.1726.0445.3254.97
Research and Development2.912.732.365.325.522.544.209.9012.47
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-12.59-13.15-12.16-18.80-22.87-20.10-24.28-44.09-54.55
Interest Expense1.330.590.000.000.000.000.01-0.00
Unusual Expense0.000.000.000.460.00-1.480.462.001.87
Net Income Before Taxes-13.10-13.96-11.98-19.02-22.59-18.07-24.68-45.13-55.76
Income Taxes-0.400.00-0.09-0.19-0.43-0.85-1.170.020.00
Consolidated Net Income-12.70-13.97-11.89-18.83-22.16-17.22-23.51-45.15-55.77
Net Income From Continuing Operations-12.70-13.97-11.89-18.83-22.16-17.22-23.51-45.15-34.70
Net Income-12.70-13.97-11.89-18.83-22.16-17.22-23.51-45.15-34.70
EPS (Recurring)-1.28-1.65-1.59-3.36-4.69-4.63-8.92-22.34-17.12
EPS (Basic, Before Extraordinaries)-1.43-1.65-1.59-3.42-4.69-4.36-9.04-23.05-17.79
EPS (Diluted)-1.43-1.65-1.59-3.42-4.69-4.36-9.04-23.05-17.79
EBITDA-11.30-11.48-10.90-17.55-22.28-19.66-23.79-43.78-54.49
Non-Operating Income (Expense)0.82-0.220.180.250.280.550.070.960.66
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.431.521.481.342.122.412.382.846.00
Price To Sales Ratio2.841.194.822.052.126.3217.4019.54184.48
Gross Margin86.1386.7584.9782.5181.1974.5950.3051.6041.71
Operating Margin-33.15-41.06-48.30-117.31-266.22-368.74-694.65-1,844.61-5,494.07
Net Margin-33.46-43.60-47.20-117.49-257.94-315.86-672.55-1,888.81-3,494.84
Shares Outstanding9.178.006.656.004.744.713.041.991.96
Market Capitalization71.2271.22107.8135.7018.2641.1471.0047.39184.17

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue9.699.459.589.248.697.386.727.05
Cost of Goods Sold Incl. D&A1.121.271.221.661.220.941.010.99
Gross Profit8.578.188.367.597.476.445.716.05
Selling, General and Administrative Excl. Other10.1310.9513.6810.5310.359.959.539.12
Research and Development0.430.820.740.920.660.510.640.81
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.56-2.77-5.32-2.94-2.88-3.51-3.82-3.07
Interest Expense0.370.320.320.320.210.000.000.00
Unusual Expense0.000.000.000.000.400.000.000.00
Net Income Before Taxes-1.47-3.06-5.59-2.98-3.40-3.67-3.90-3.20
Income Taxes-0.130.00-0.320.050.000.00-0.050.03
Consolidated Net Income-1.34-3.06-5.27-3.04-3.40-3.67-3.85-3.23
Net Income From Continuing Operations-1.34-3.06-5.27-3.04-3.40-3.67-3.85-3.23
Net Income-1.34-3.06-5.27-3.04-3.40-3.67-3.85-3.23
EPS (Recurring)-0.13-0.33-0.59-0.38-0.37-0.44-0.47-0.49
EPS (Basic, Before Extraordinaries)-0.13-0.33-0.59-0.38-0.40-0.44-0.47-0.49
EPS (Diluted)-0.13-0.33-0.59-0.38-0.40-0.44-0.47-0.49
EBITDA-1.52-2.74-5.27-1.77-2.73-3.35-3.63-2.49
Non-Operating Income (Expense)0.460.030.040.280.09-0.17-0.08-0.13
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.490.760.820.370.410.400.430.41
Price To Sales Ratio2.842.201.551.121.401.592.104.28
Gross Margin88.4786.5387.2782.0785.9787.2884.9285.89
Operating Margin-16.06-29.33-55.47-31.82-33.19-47.50-56.88-43.59
Net Margin-13.82-32.37-55.00-32.84-39.19-49.74-57.37-45.81
Shares Outstanding9.179.008.138.007.647.477.426.65
Market Capitalization71.2271.6748.7435.8637.5439.1849.64107.81

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments11.6112.2210.5817.9634.6922.6324.0668.5637.17
Short Term Receivables1.031.370.720.400.440.270.500.270.10
Inventories1.631.682.161.981.360.880.891.950.33
Other Current Assets1.401.040.840.831.051.291.091.920.57
Total Current Assets15.6716.3014.2921.1737.5425.0626.5372.7038.18
Net Property, Plant & Equipment2.953.900.710.610.760.761.780.380.17
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets-------0.000.00
Deferred Tax Assets0.891.150.280.310.40-0.62--
Other Assets0.050.271.102.974.535.697.150.420.89
Total Assets19.5621.6216.3925.0643.2331.5236.0973.5039.23
Short Term Debt Incl. Current Port. of LT Debt0.380.360.090.070.061.010.600.000.00
Accounts Payable2.711.832.162.131.542.085.212.700.84
Income Tax Payable--0.27------
Other Current Liabilities8.266.965.604.843.882.803.344.375.28
Total Current Liabilities11.359.158.127.045.495.899.147.076.12
Long Term Debt9.033.770.540.620.701.981.420.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.891.150.280.310.40-0.62--
Other Liabilities0.000.000.000.000.000.000.000.250.31
Total Liabilities21.2714.078.957.986.597.8711.197.326.43
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00122.27
Common Equity-1.717.547.4417.0936.6523.0124.2665.55-90.07
Total Shareholders Equity-1.717.547.4417.0936.6523.0124.2665.5532.20
Accumulated Minority Interest0.000.000.000.000.000.640.640.640.60
Total Equity-1.717.547.4417.0936.6523.6424.9066.1932.81
Total Liabilities & Stockholders Equity19.5621.6216.3925.0643.2331.5236.0973.5039.23
Book Value Per Share-0.211.131.243.607.777.5812.2033.39-47.89
Tangible Book Value Per Share-0.211.131.243.607.777.5812.2033.39-47.89
Full-Time Employees837368625245519148
Price to Book Ratio-28.2414.293.230.821.123.091.952.812.10
Return on Assets-67.84-62.55-90.88-64.90-46.07-69.55-82.39-61.56-179.61
Return on Equity-478.70-158.63-153.57-82.49-57.72-99.47-100.54-71.00-294.99
Return on Invested Capital-190.82-105.01-236.04-125.13-46.10-94.07-175.80-52.94-111.15
Quick Ratio1.241.601.492.726.604.112.8010.006.19
Current Ratio1.381.781.763.016.844.262.9010.286.24

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-12.70-13.97-11.89-18.83-22.16-17.22-23.51-45.15-55.77
Depreciation1.281.681.261.020.600.440.770.310.07
Other Funds (Non Cash)3.022.781.922.332.881.534.452.348.88
Funds from Operations-8.40-9.51-8.71-15.48-18.69-15.26-18.29-42.50-46.82
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-2.491.321.760.812.041.63-1.81-2.57-0.29
Cash from Operating Activities-10.89-8.19-6.95-14.67-16.64-13.63-20.10-45.07-47.11
Capital Expenditures-0.01-0.070.00-0.210.000.000.00-0.07-0.28
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments3.903.94-8.520.000.0018.22-7.9651.04-36.55
Purchase of Investments0.000.00-8.520.000.00-5.08-24.46-37.22-81.06
Sale Or Maturity of Investments3.903.940.000.000.0023.3016.5088.2744.51
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities3.893.88-8.52-0.210.0018.22-7.9650.97-36.83
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock5.220.228.678.140.0025.6817.490.0578.33
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock5.220.228.678.140.0025.6817.490.0578.33
Proceedsfrom Stock Options3.910.120.008.140.0025.6817.490.0078.33
Issuance or Reduction of Debt, Net0.007.410.000.000.000.001.460.110.00
Change in Long Term Debt0.007.410.000.000.000.000.000.000.00
Issuance of Long Term Debt0.007.410.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00-0.23-0.660.000.000.000.000.00
Other Financing Activities Uses0.000.00-0.23-0.660.000.000.000.000.00
Cash from Financing Activities5.227.638.447.490.0025.6818.950.1678.33
Exchange Rate Effect-0.020.020.150.01-0.080.18-0.21-0.10-0.02
Net Change in Cash-1.803.33-6.88-7.38-16.7330.45-9.325.96-5.62
Free Cash Flow-10.90-8.25-6.95-14.87-16.64-13.63-20.10-45.14-47.39
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments7.5010.048.8311.6113.207.39
Short Term Receivables1.620.910.871.031.480.81
Inventories3.962.421.981.631.211.43
Other Current Assets1.370.750.851.401.460.92
Total Current Assets14.4514.1212.5315.6717.3510.56
Net Property, Plant & Equipment2.762.892.902.953.823.86
Total Investments and Advances0.000.000.000.000.000.00
Deferred Tax Assets---0.89--
Other Assets0.050.050.050.050.240.14
Total Assets17.2617.0615.4819.5621.4114.56
Short Term Debt Incl. Current Port. of LT Debt0.701.380.630.380.470.41
Accounts Payable3.442.182.172.713.072.57
Other Current Liabilities6.648.119.518.268.616.65
Total Current Liabilities10.7811.6712.3111.3512.149.62
Long Term Debt8.998.188.869.0310.343.83
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.89--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities19.7719.8521.1721.2722.4813.45
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-2.51-2.79-5.69-1.71-1.071.11
Total Shareholders Equity-2.51-2.79-5.69-1.71-1.071.11
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-2.51-2.79-5.69-1.71-1.071.11
Total Liabilities & Stockholders Equity17.2617.0615.4819.5621.4114.56
Book Value Per Share-0.27-0.31-0.70-0.21-0.140.15
Tangible Book Value Per Share-0.27-0.31-0.70-0.21-0.140.15
Full-Time Employees---83--
Price to Book Ratio-28.24-12.34-28.24-31.9133.218.98
Return on Assets-65.70-93.41-97.59-67.84-66.70-71.79
Return on Equity----478.70-337.84-210.58
Return on Invested Capital-20.67-56.75-166.33-41.47-36.73-74.30
Quick Ratio0.971.000.861.241.330.95
Current Ratio1.341.211.021.381.431.10

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-1.34-3.06-5.27-3.04-3.40-3.67
Depreciation0.030.030.051.170.150.16
Other Funds (Non Cash)0.520.941.150.410.531.18
Funds from Operations-0.79-2.09-4.07-1.45-2.72-2.34
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-2.04-1.431.07-0.091.051.71
Cash from Operating Activities-2.83-3.52-3.01-1.54-1.67-0.62
Capital Expenditures0.00-0.00-0.000.00-0.00-0.03
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.352.430.600.52-1.320.21
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.352.430.600.52-1.320.21
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.352.430.600.52-1.330.18
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.294.740.23-0.04-0.000.04
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.294.740.23-0.04-0.000.04
Proceedsfrom Stock Options0.083.870.00-0.040.160.00
Issuance or Reduction of Debt, Net0.000.000.000.007.410.00
Change in Long Term Debt0.000.000.000.007.410.00
Issuance of Long Term Debt0.000.000.000.007.410.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.08-0.04
Other Financing Activities Uses0.000.000.000.000.08-0.04
Cash from Financing Activities0.294.740.23-0.047.480.00
Exchange Rate Effect-0.00-0.01-0.00-0.01-0.010.03
Net Change in Cash-2.193.65-2.18-1.074.48-0.40
Free Cash Flow-2.83-3.52-3.01-1.54-1.67-0.65

Revenue breakdown

License2024: 65.00K 2025: 65.00K
Product2024: 25.12M 2025: 31.97M
Japan2024: 65.00K 2025: 65.00K
Other Countries2024: 119.00K 2025: 197.00K
United Kingdom2024: 1.67M 2025: 1.70M
United States2024: 23.33M 2025: 30.08M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.80%0.4M6.2M87.42K
2026-10-155.75%0.3M6.1M83.68K
2026-09-305.19%0.3M6.1M88.12K
2026-09-155.32%0.3M6.1M84.74K
2026-08-315.29%0.3M6.2M101.70K
2026-08-145.23%0.3M6.2M119.26K
2026-07-315.86%0.4M6.0M109.82K
2026-07-156.51%0.4M5.7M109.79K
2026-06-303.93%0.2M5.2M106.65K
2026-06-153.98%0.2M5.2M104.53K
2026-05-295.56%0.3M5.0M85.98K
2026-05-155.66%0.3M5.1M65.24K
2026-04-306.54%0.3M5.1M59.50K
2026-04-156.72%0.3M5.1M70.47K
2026-03-315.74%0.3M5.1M68.55K
2026-03-135.16%0.3M5.1M64.24K
2026-02-275.20%0.3M5.0M59.82K
2026-02-135.26%0.3M5.0M57.43K
2026-01-305.37%0.3M5.0M70.81K
2026-01-155.47%0.3M5.1M59.25K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-184/A2026-09-11SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-098-KCurrent report2026-09-08SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-20DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-20SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-04-23SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-27144Filing for proposed sale of securities under Rule 144.SEC
2026-05-27144Filing for proposed sale of securities under Rule 144.SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-22SEC
2026-05-14144Filing for proposed sale of securities under Rule 144.SEC
2026-05-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-068-KCurrent report2026-05-06SEC
2026-05-05SCHEDULE 13GSEC
2026-05-05144Filing for proposed sale of securities under Rule 144.SEC
2026-04-23144Filing for proposed sale of securities under Rule 144.SEC
2026-04-15DNotice of sales of securities on Form D (Regulation D)SEC
2026-04-144Statement of changes in beneficial ownership of securities2026-04-13SEC
2026-04-144Statement of changes in beneficial ownership of securities2026-04-10SEC
2026-04-143Initial statement of beneficial ownership of securities2026-04-13SEC
2026-04-014Statement of changes in beneficial ownership of securities2026-04-01SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0949.08K100
2026-0849.27K1200.12K3
2026-070000
2026-060000
2026-0559.85K179.50K2
2026-0400640.75K2
2026-030000
2026-020000
2026-010000
2025-124.84K112.63K1
2025-110013.39K1

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC2.55%
FourWorld Capital Management LLC1.13%
WEXFORD CAPITAL LP1.11%
NORTHERN TRUST CORP0.80%
JANE STREET GROUP, LLC0.76%
GEODE CAPITAL MANAGEMENT, LLC0.76%
Jaffetilchin Investment Partners, LLC0.72%
Wealthspire Advisors, LLC0.57%
CITADEL ADVISORS LLC0.53%
MARSHALL WACE, LLP0.53%

Funds

Fund% owned
Avantis International Small Cap Value ETF11.74%
Avantis International Equity ETF4.30%
Federated Hermes SDG Engagement Equity Fund1.84%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.70%
VANGUARD EXTENDED MARKET INDEX FUND0.74%
Fidelity Extended Market Index Fund0.36%
Ultra-Small Company Fund0.30%
Avantis International Small Cap Equity ETF0.29%
Avantis International Equity Fund0.27%
Avantis International Small Cap Value Fund0.22%

OakChart. ECOR. Cached 15 minutes.